201 related articles for article (PubMed ID: 19738163)
1. PARP inhibitors: will the new class of drugs match the hype?
Tuma RS
J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
[No Abstract] [Full Text] [Related]
2. An Achilles' heel for breast cancer?
Caldecott KW; Chalmers A
Nat Struct Mol Biol; 2005 May; 12(5):387-8. PubMed ID: 15870726
[No Abstract] [Full Text] [Related]
3. PARP inhibitors: targeting the right patients.
Azvolinsky A
J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
[No Abstract] [Full Text] [Related]
4. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
Stebbing J; Ellis P; Tutt A
Future Oncol; 2010 Apr; 6(4):485-6. PubMed ID: 20373860
[No Abstract] [Full Text] [Related]
5. PARP inhibition in breast cancer.
Garber J
Clin Adv Hematol Oncol; 2009 Sep; 7(9):573-5. PubMed ID: 20020667
[No Abstract] [Full Text] [Related]
6. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Mercier-Vogel L; Bodmer A; Castiglione M
Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Carden CP; Yap TA; Kaye SB
Curr Opin Oncol; 2010 Sep; 22(5):473-80. PubMed ID: 20485165
[TBL] [Abstract][Full Text] [Related]
8. No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers.
Rashid MU; Torres D; Zaidi A; Rasheed F; Sultan F; Shakoori AR; Amin A; Hamann U
Breast Cancer Res Treat; 2008 Jan; 107(1):155-6. PubMed ID: 18043900
[No Abstract] [Full Text] [Related]
9. [Role of oncogenetics in the treatment of breast and ovarian cancer].
Langmár Z; Németh M
Orv Hetil; 2011 Jul; 152(30):1214-5. PubMed ID: 21733796
[No Abstract] [Full Text] [Related]
10. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P; Jonkers J
Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
[TBL] [Abstract][Full Text] [Related]
12. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
13. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
14. Cancer: crossing over to drug resistance.
Livingston DM; Silver DP
Nature; 2008 Feb; 451(7182):1066-7. PubMed ID: 18305536
[No Abstract] [Full Text] [Related]
15. Development of PARP inhibitors: an unfinished story.
Patel A; Kaufmann SH
Oncology (Williston Park); 2010 Jan; 24(1):66, 68. PubMed ID: 20187324
[No Abstract] [Full Text] [Related]
16. Clinical management of BRCA1 and BRCA2 mutation carriers.
Domchek SM; Armstrong K; Weber BL
Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
[No Abstract] [Full Text] [Related]
17. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
18. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.
Domchek SM; Mitchell G; Lindeman GJ; Tung NM; Balmaña J; Isakoff SJ; Schmutzler R; Audeh MW; Loman N; Scott C; Friedlander M; Kaufman B; Garber JE; Tutt A; Robson ME
J Clin Oncol; 2011 Nov; 29(32):4224-6. PubMed ID: 21931031
[No Abstract] [Full Text] [Related]
19. Foreword. Poly(ADP-ribose) polymerase inhibitors in clinical development.
Kummar S
Curr Probl Cancer; 2011; 35(1):6. PubMed ID: 21300206
[No Abstract] [Full Text] [Related]
20. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
